High specificity is a key parameter for copper ligands as
future therapeutic agents for Alzheimer's, Wilson's, and
cancer diseases

Anne Robert, Yan Liu, Michel Nguyen, Françoise Benoit-Vical, Bernard Meunier

► To cite this version:

Anne Robert, Yan Liu, Michel Nguyen, Françoise Benoit-Vical, Bernard Meunier. High specificity is a key parameter for copper ligands as future therapeutic agents for Alzheimer's, Wilson's, and cancer diseases. Comptes Rendus. Chimie, 2025, 28 (G1), pp.755-769. 10.5802/crchim.417. hal-05325367

HAL Id: hal-05325367

https://hal.science/hal-05325367v1

Submitted on 22 Oct 2025

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
# Comptes Rendus
Chimie

Anne Robert, Yan Liu, Michel Nguyen, Françoise Benoit-Vical
and Bernard Meunier

**High specificity is a key parameter for copper ligands as future therapeutic agents for Alzheimer's, Wilson's, and cancer diseases**

Volume 28 (2025), p. 755-769

Online since: 21 October 2025

https://doi.org/10.5802/crchim.417

<figure><img src="image_2.png" /></figure>

This article is licensed under the

CREATIVE COMMONS ATTRIBUTION 4.0 INTERNATIONAL LICENSE.

http://creativecommons.org/licenses/by/4.0/
Review article

# High specificity is a key parameter for copper ligands as future therapeutic agents for Alzheimer's, Wilson's, and cancer diseases

Anne Robert<sup>®,*,a</sup>, Yan Liu<sup>®,*,b</sup>, Michel Nguyen<sup>®,a</sup>, Françoise Benoit-Vical<sup>®,a</sup> and Bernard Meunier<sup>®,*,a,b</sup>

<sup>a</sup> Laboratoire de Chimie de Coordination du CNRS, LCC-CNRS, Inserm ERL 1289 MAAP, Université de Toulouse, 205 route de Narbonne, 31077 Toulouse cedex, France

<sup>b</sup> School of Chemical Engineering and Light Industry, Guangdong University of Technology, Higher Education Mega Center, Guangzhou 510006, PR China

E-mails: anne.robert@lcc-toulouse.fr, yanliu@gdut.edu.cn, michel.nguyen@lcc-toulouse.fr, francoise.benoit-vical@lcc-toulouse.fr, bmeunier@lcc-toulouse.fr

*This review is dedicated to Dr. Marguerite Pitié, † 2011, in memoriam*

**Abstract.** The loss of copper homeostasis is considered a characteristic feature of several major human diseases such as Alzheimer's, Wilson's, or cancer diseases. Consequently, the design of new efficient ligands targeting copper regulation is a major concern of therapeutic bioinorganic chemistry and should take in consideration the chelator structures for being copper-specific and the redox properties of the corresponding complexes to obtain suitable pharmacological activities. As an improvement of previously developed amine ligands, N4-tetradentate 8-aminoquinoline chelators, are able to inhibit memory and behavior impairment in Alzheimer mice, by generating square planar Cu(II) complexes suitable for the efficient extraction of copper ions from metallated amyloid peptides, leading to a reduction of the neurotoxic oxidative stress in the brain. These chelators also reverse the hepatotoxic accumulation of copper in animals with Wilson's disease and inhibit the proliferation and migration of human cancer cell lines. This review summarizes the gradual and logical development of twenty-five years of research in our group on copper-specific chelators and their promising development as potential therapeutic tools against diseases in which copper is involved.

**Keywords.** Alzheimer's disease, Cancer, Chelator, Copper, Medicinal chemistry, Redox metal, Wilson's disease.

**Funding.** CNRS, Inserm, GDUT.

**Note.** Article submitted by invitation.

Manuscript received 20 August 2025, revised 30 August 2025, accepted 1 September 2025.

## 1. Introduction: copper in human health and disease

After iron and zinc, copper is the third essential metal ion in living systems [1]. The highest concentrations of copper are found in liver and brain. The copper concentration in human frontal lobe and cerebellum is ranging from 60 to 110 µM [2]. In living organisms,

copper exists in the oxidized Cu(II) and reduced Cu(I) forms. In biological conditions, the interconversion between these two oxidation states is easy and facilitates the role of this metal as catalytic co-factor in various copper enzymes involved in electron transfers and oxidations.

Copper ions are found in many different metalloenzymes (laccases, tyrosinase, superoxide dismutase, ascorbate oxidase, cytochrome-c oxidase

<footnote>* Corresponding authors</footnote>
<figure><img src="image_3.png" /><figcaption>**Scheme 1.** Step-by-step reduction of dioxygen catalyzed by low-valent transition metals such as Cu(I) or Fe(II).</figcaption></figure>

to cite a few ones) and metalloproteins (hemocyanin, ceruloplasmin) [3,4]. Among these copper proteins involved in vital processes, cytochrome-c oxidase is a large transmembrane terminal heme/copper oxidase of the respiratory electron transport chain. Its redox centers involved in electron transport consist of two heme moieties and two copper centers that catalyze the reduction of dioxygen to water with the concomitant pumping of four protons through the mitochondrial membrane [5] (Equation (1)).

$$O_2 \xrightarrow{4e^-, 4H^+} 2H_2O \quad (1)$$

Since the air-stable oxidation state +II of copper can be easily reduced to the highly reactive state (+I) by endogenous reducing agents (e.g., ascorbate, glutathione, NADPH) [6], its acquisition, distribution and regulation in living systems is strictly controlled by copper carriers and chaperone proteins [7]. As a low-valent transition metal ion, Cu(I) behaves in the same way as Fe(II), being able to induce the electron-by-electron reduction of dioxygen to water in all aerobic organisms (Scheme 1). This catalytic reaction is potentially deleterious because it produces superoxide radical anion $O_2^-$, then hydrogen peroxide $H_2O_2$ and finally hydroxyl radical $HO^*$, the most aggressive form among the reactive/reduced oxygen species (ROS).

Superoxide is a relatively mild reductant and hydrogen peroxide is the required cofactor of the ubiquitous peroxidases. In healthy organisms, the concentrations of superoxide and hydrogen peroxide are strictly controlled by metallo-enzymes. The efficient superoxide dismutases (SODs), Cu/Zn-superoxide dismutase (= SOD-1), to name one of them, have a key role in the regulation of this metabolic pathway, by converting two superoxide radical anions to molecular oxygen and hydrogen peroxide through

the redox activity of its copper centre, while zinc plays a structural role (Equation (2)).

Cu/Zn-SOD (= SOD-1) is present in nearly all compartments of human cells, nucleus, mitochondria, cytosol, and peroxisomes.

$$2O_2^{\bullet-} \xrightarrow{2H^+} O_2 + H_2O_2 \quad (2)$$

Hydrogen peroxide is used as cofactor by peroxidases, but any excess of production of this peroxide is controlled by catalases that are highly efficient at $H_2O_2$ disproportionation. In the case of $H_2O_2$ overproduction, the three-electron reduction product of dioxygen, hydroxyl radical $HO^*$, is produced. This radical is the strongest oxidizing agent (standard redox potential = 2.8 V/NHE) after fluorine gas (2.9 V/NHE) and, unlike $O_2^{\bullet-}$ or $H_2O_2$, no specific detoxifying enzymes exist for $HO^*$. At diffusion-controlled rates, $HO^*$ hydroxylates aliphatic C-H bonds, or performs the one-electron oxidation of rather inert molecules, or modifies unsaturated compounds by addition [8]. All biomolecules of living organisms can be quickly oxidized by $HO^*$, leading to extensive damage up to cell death. The only way to prevent the formation of this deleterious radical is to control the upstream reduction of molecular oxygen. Involvement of an oxidative stress induced by misregulated copper in the brain has been documented as a key feature of Alzheimer's disease and proposed to be important for the development of the brain pathology [9-11]. It is also well known that the deregulation of copper homeostasis is involved in other inherited or sporadic neurodegenerative pathologies like Parkinson's disease, amyotrophic lateral sclerosis that is caused by mutations of SOD-1 [12], or prion-mediated encephalopathies [13]. Copper ions are also essential for the function of several brain metalloenzymes like tyrosinase [14] or dopamine β-hydroxylase [15].

In addition, any deficiency of a human copper carrier protein involved in the regulation of copper uptake, may generate a pathology. This is the case for Wilson's disease, a genetic condition caused by mutations of the *Atp7b* gene coding for the copper carrier ATP7B in charge of excreting copper from liver to bile. Impairment of ATP7B causes massive accumulation of copper in liver, brain, and other organs, resulting in liver disease and neurological disorders [16-18]. Moreover, copper is essential for efficient iron and zinc trafficking in mammals. The major copper
transporter ceruloplasmin exhibits a ferroxidase activity that promotes the Fe(II) oxidation to facilitate the iron loading into ferritin, and Zn(II) is a substrate of ferroportin [19]. So it should be noted that the roles of these three vital metal ions, copper, zinc, and iron, are often interconnected in different proteins or enzymes. Consequently, any metal chelator, if considered as drug candidate, should be specific for one of these metal ions to avoid as much as possible perturbations of metalloproteins dependent on the two other metal ions. This is a prerequisite point in the rational design of a copper ligand for being beneficial in the therapy of a copper-related disease.

As bioinorganic chemists initially involved in DNA cleavage by metal complexes, our group became interested by using copper complexes as DNA cleavers (Section 2 of the present review article), then some copper ligands were designed for antitumor activity (Sections 3 and 6). Different series of specific copper chelators were then developed as potential drugs to treat Alzheimer's disease (Section 4) and Wilson's disease (Section 5). In relation to the state of the art, the present review is therefore focused on the last twenty-five years of research on copper ligands with potential therapeutic interest performed in our research group, especially on the step-by-step rational design of metal-selective and biologically efficient drugs.

## 2. Copper complexes as DNA cleavers

Among the various metal complexes developed over the last three decades as artificial nucleases, copper complexes of 1,10-phenanthroline (Phen) have been widely used as DNA cleavers [20–24]. The versatile Phen ligand is able to chelate copper ions as redox-active Cu(Phen) and Cu(Phen)₂ complexes (for a general review on the chemistry of phenanthrolines, see Ref. [24]). Interaction of the redox-active Cu(I)/Cu(II)-phenanthroline complexes in the minor groove of double-stranded DNA in the presence of H₂O₂, triggers the oxidation of C1' and C4' of 2-deoxyribose units, resulting in single-strand DNA cleavage [20,21]. This cleavage can also be achieved by aerobic oxidation in the presence of a reducing agent. Cu(Phen)₂ was found significantly more active than Cu(Phen), but the association constant for the second Phen ligand onto the copper ion is too low to

enhance DNA oxidation at submicromolar concentrations (log K<sub>app</sub> = 5.5) [25]. Consequently, chelators named “Clip-Phen” were prepared, containing two Phen residues linked through their C2 or C3 positions by an adjustable bridge, to favor the coordination of two Phen units around a single copper ion (Figure 1) [26,27]. The efficiency of oxidative DNA cleavage by Cu-Clip-Phen complexes, under aerobic and physiological conditions in the presence of a reducing agent, was evaluated by quantification of the cleavage of supercoiled circular bacteriophage ΦX174 DNA (form I) into relaxed (form II) and circular (form III) forms. In these conditions, Cu-Clip-Phen complexes exhibited a nuclease activity that was dramatically higher than that of Cu-1,10-phenanthroline [26].

The DNase activity of Clip-Phen was higher when the bridge was linked at the C3 position of the Phen moiety (3-Clip-Phen series) compared to the C2 position (2-Clip-Phen series) and when the bridge contained three methylene units [27,28]. The most efficient chelator of this series was 3-Clip-Phen (Figure 1) with a serinol bridge at C3 position of the Phen rings, being 20–30 times more active as DNA cleaver than its 2-Clip-Phen analog [27,28]. In fact, 2-Clip-Phen in the presence of CuCl₂ (1:1 molar ratio) resulted in an incomplete (70%) cleavage of ΦX174 form I into relaxed form II (30% of remaining form I) whereas, in the same conditions, 3-Clip-Phen resulted in the complete cleavage of form I into form II (35%) and circular form III (65%), with an intense smear corresponding to smaller DNA fragments.

In addition, the serinol bridge between the two Phen units allowed, via its primary aliphatic amine, the vectorization and modulation of the binding domain in these DNA cleavers. As expected, the attachment of spermine, which has high affinity for the minor groove of double helix DNA, to 2-Clip-Phen

<figure><img src="image_4.png" /><figcaption>**Figure 1.** Structures of the covalently linked bis-phenanthroline ligands, 2-Clip-Phen and 3-Clip-Phen.</figcaption></figure>
afforded a new spermine–phenanthroline conjugate with an enhanced nuclease efficacy [29].

The electrochemical study of the 2- and 3-Clip-Phen series indicated that the 2-Clip-Phen ligands are better to stabilize the tetrahedral Cu(I) state of their complexes in comparison to the Cu(II) state. On the other hand, 3-Clip-Phen derivatives facilitate the stabilization of the corresponding Cu(II) complexes with a quasi-irreversible Cu(II) → Cu(I) reduction, suggesting that the reduced DNA cleavage efficacy of Cu-2-Clip-Phen complexes might be correlated with the higher stabilization of the cuprous oxidation state. However, the absence of strict correlation between the redox properties of the copper complexes and their DNA cleavage efficacy suggests that steric or electrostatic parameters of the DNA interactions also take part in the modulation of the nuclease activity of these copper complexes.

Noteworthy, several complexes of 2- or 3-Clip-Phen with Cu(II) crystallized as a double-helical structure of stoichiometry Cu₂L₂, while monomeric CuL species, with various geometries, were predominant in solution [28]. The structure and reactivity of these copper complexes appear to be particularly versatile, a feature that opens the way for potential uses as biological tools.

### 3. Copper ligands/complexes with antitumor activity

Since the registration of cisplatin in the early 1980s, the role of metal ligands and complexes in cancer research has been the subject of many studies until now (for a recent review, see Ref. [30]). The efficacy of the copper complexes of Clip-Phen as DNA cleavers suggested that these chelators might also be considered as therapeutic agents against cancer. In fact, research on the cytostatic and potential antitumor activities of substituted Phen derivatives or related ligands metalated with copper or other various metals has been investigated in parallel to their DNase activity [31–34] and has remained an active research field until recent years, with the aim of developing novel metal-based anticancer drugs [35–37].

In this context, the cytostatic properties of a series of 3-Clip-Phen derivatives were evaluated on the classic L1210 murine leukemia cell line. The concentration inhibiting the cell growth by 50% after 48 h (IC₅₀) of 3-Clip-Phen was close to that of Phen itself

<figure><img src="image_5.png" /><figcaption>**Figure 2.** Structures of alkyl substituted 3-Clip-Phen ligands, and 3,8-substituted-1,10-phenanthrolines.</figcaption></figure>

(1.15 and 2.5 µM, respectively), although Cu-3-Clip-Phen was a better DNA cleaver than Cu(Phen)₂ [33]. This result suggested that the cytostatic activity was not strictly correlated to the DNase activity.

Conversely, 3-propyl-Clip-Phen, with a simple aliphatic linker (Figure 2), exhibited a significantly higher activity against L1210 cells (IC₅₀ = 0.25 µM) compared to 3-Clip-Phen (Figure 1). Analogs of 3-propyl-Clip-Phen containing two to five methylene units in the linker (3-alkyl-Clip-Phen series) (Figure 2), were also evaluated. Their activity was significantly correlated to their number of methylene units in the linker, itself correlated to hydrophobicity (Figure 3). The longer the linker, the more active the compound was, with an IC₅₀ value of 0.13 µM for 3-pentyl-Clip-Phen. In order to investigate whether the hydrophilic primary amine of the linker of 3-Clip-Phen (log Pₐelle = 2.47, IC₅₀ = 1.15 µM) could hamper its biological activity, this ligand was compared to the slightly more hydrophobic 3-acetyl-Clip-Phen (log Pₐelle = 2.80). However, the antiproliferative activity of 3-acetyl-Clip-Phen was lower at 5 µM, indicating that the correlation between biological activity and log Pₐelle was limited to the 3-aliphatic-Clip-Phen series [33].

The putative role of the alkoxy substituent at the C3-position in the phenanthroline of Clip-Phen derivatives was evaluated by comparing their activities to that of monomeric Phen derivatives, 3-methoxy- and 3,8-dimethoxy-1,10-phenanthroline. The IC₅₀ values of 3-methoxy- and 3,8-dimethoxy-1,10-phenanthroline were 1.5 µM and 1.4 µM, respectively, in the same range as for Phen itself (2.5 µM), suggesting that the alkoxy substituents at the C3- and C8-position were not responsible for the higher cytostatic activity of 3-alkyl-Clip-Phen. On the other hand, the attachment position of the linker on the
<figure><img src="image_6.png" /><figcaption>**Figure 3.** Antiproliferative activity of 3-alkyl-Clip-Phen derivatives measured as 1/IC₅₀ value with respect to the number of methylene units in the linker (n, blue trace) or to the hydrophobicity (log Pcalc, red trace). The dotted lines stand for polynomial trend curves of degree 2.</figcaption></figure>

phenanthroline units is an important parameter, since 2-propyl-Clip-Phen exhibited a much poorer activity (IC₅₀ value > 100 µM) than its regio-isomer 3-propyl-Clip-Phen (1.15 µM) [33].

The conjugation of 3-Clip-Phen with DNA binders and/or cell penetration agents such as spermine or polyarginine (Arg)₉ did not increase the antiproliferative activity. The IC₅₀ values of 3-Clip-Phen–spermine and 3-Clip-Phen–(Arg)₉ were 12 µM and 1.9 µM, respectively, against L1210 cells [33], despite the fact that 3-Clip-Phen–spermine exhibited a much higher nuclease activity than 3-Clip-Phen on supercoiled ΦX174 DNA [29].

Importantly, Cu(II) complexes of Clip-Phen derivatives were prepared, and their cytostatic activities were evaluated. While complexation of copper failed to improve the activity of 3-Clip-Phen derivatives regardless of the composition of the linker, the activity of 2-propyl-Clip-Phen dramatically increased with copper complexation (IC₅₀ = 2 µM, compared to IC₅₀ > 100 µM for the free ligand). These results confirmed that the attachment position of the linker induced large variations in the biological properties of Clip-Phen derivatives [33].

**4. Copper chelators against Alzheimer's disease**

Among the various putative targets involved in Alzheimer's disease (AD), the loss of metal ion homeostasis in AD brain is well documented [38–41]. Post-mortem analyses of the brain of patients

with AD indicated that amyloid plaques contain an excess of copper, iron, and zinc by a factor of 5.7, 2.8, and 3.1, respectively, compared to the levels of normal brains [9]. Copper–amyloid complexes, in the presence of endogenous reductants, catalyze the reduction of dioxygen to generate reduced ROS (Scheme 1) [40,42]. Production of ROS is the molecular signature of chronic inflammation reported in AD brain and involved in neuronal death [43]. In addition, copper ions sequestered in amyloid plaques may be responsible for a deficit in copper for cerebral copper-dependent enzymes, like superoxide dismutase-1, [44] or copper oxidases involved in the biosynthesis of neurotransmitters. Therefore, restoration of copper homeostasis in the brain is a multifunction drug target that requires the design of specific chelators [11,38,45,46]. Because of the deleterious oxidative stress catalyzed by out-of-control redox-active metal ions, this approach should be considered an essential strategy among all various attempts in AD drug design.

**4.1. Clioquinol (CQ) and PBT2**

The 8-hydroxyquinoline derivatives clioquinol (CQ) and PBT2 (Figure 4) have been the first copper/zinc ligands considered as potential anti-AD agents to limit the interactions between metal ions and amyloid peptide (Aβ). Clioquinol was able to decrease Aβ deposits in brain and to improve learning and memory abilities of transgenic AD mice [47,48]. Unfortunately, this simple chelator, previously used as antifungal and antiprotozoal drug, was withdrawn from the market in 1983, due to its neurotoxicity attributed to zinc chelation [15,49]. In fact, the 8-hydroxyquinolines are non-specific metal chelators [50,51], and the affinity constant of CQ for Cu(II) is only one order of magnitude higher than that for Zn(II) (log K = 10 and 9, respectively) [38,52]. In this series, PBT2 [38] was less toxic [48]. However, phase II clinical trial of PBT2 as anti-AD drug was stopped due to its lack of efficacy [53].

In fact, CQ and PBT2 are bi- or tridentate ligands. Consequently, their corresponding Cu(II) complexes have a 1:2 metal/ligand stoichiometry [38,54]. Moreover, addition of stoichiometric amounts of CQ or PBT2 to Cu(II)–Aβ in vitro does not efficiently remove Cu from Cu(II)–Aβ, but generates stable ternary CQ– or PBT2– Cu(II)–Aβ complexes [54,55]. Since
<figure><img src="image_7.png" /><figcaption>**Figure 4.** Structures of copper chelators developed as drugs against Alzheimer's disease. Z stands for an adjustable linker.</figcaption></figure>

8-hydroxyquinolines are unable to extract copper(II) from soluble amyloids, these ligands should not be considered as regulators of the copper homeostasis in AD brains. Moreover, their flexible coordination properties allow them to accommodate either Cu(II) or Cu(I), reducing their capacity to inhibit the oxidative stress induced by Cu-Aβ [56].

Additionally, copper is a required cofactor for several essential metalloenzymes, for example, for the tyrosinase that produces L-DOPA from tyrosine and catecholamine neurotransmitters [14]. Circadian rhythm dysfunction occurs in AD, and copper was recently reported to modulate rest-activity cycles via norepinephrine produced by copper enzyme dopamine β-hydroxylase [15]. These data indicate that the chance to get an efficient copper ligand from the shelves to treat copper-related disease are limited, due to the necessity of understanding the whole picture of the various parameters in copper coordination chemistry. Specific copper chelators should result from a rational design in order to create drugs as specific as possible. These ligands should not disrupt the regular activity of copper enzymes or proteins and must have suitable pharmacological and safety profiles. Moreover, they should be able to cross the blood-brain barrier after an oral administration, to avoid any painful mode of administration. The following sections are reporting our successive works to reach this goal.

## 4.2. Bis(8-hydroxyquinolines)

In line with our expertise on Clip-Phen as copper chelators endowed with nuclease and cytostatic

activities (see above), we prepared a series of chelators using two 8-hydroxyquinoline motifs covalently linked at their C2 position. Contrary to mono(8-hydroxy)quinolines, bis(8-hydroxy)quinolines (Figure 3) offer tetradentate $N_2O_2$ binding sites to form copper complexes with a ligand/metal ratio = 1:1. The affinity of bis(8-hydroxyquinolines) for Cu(II) is higher than that of mono(8-hydroxy)quinolines by 4 to 6 orders of magnitude, with $log K_{app}$ of 15.5–16.6 at physiological pH [57,58]. However, their selectivity for copper with respect to zinc is only 100 to 1000 [$log K_{app}$ for Zn(II) = 12.5–14.2]. These ligands are efficient at solubilizing Aβ peptides and are able to inhibit $H_2O_2$ production by the Cu-Aβ/ascorbic acid system. These results were superior to those obtained with the corresponding 8-hydroxyquinoline monomers, thus validating the strategy of tetradentate chelators. However, their affinity for Zn(II) is still too high to consider these ligands as biologically pertinent copper regulators [59].

## 4.3. Bis(8-aminoquinolines)

To proceed to the transfer of copper from Aβ to glutathione (an efficient copper carrier) and, therefore, to restore the copper homeostasis in AD brains, we designed a series of tetradentate ligands L based on a bis(8-aminoquinoline) scaffold, which are specific for copper coordination (Figure 4, PA1637, 1, 2) [11]. These ligands have a high affinity for Cu(II) ions, with $log K_{app}$ values ranging from 14 to 16 at pH 7.4, and a low affinity for Zn(II), resulting in very high selectivity for Cu(II) with respect to Zn(II), with a log [$K_{app}$ (Cu-L)/$K_{app}$ (Zn-L)] value over 12 [60]. In vitro, at micromolar concentrations, they efficiently extract Cu(II) from Cu(II)-Aβ, to provide the Cu(II)-L complex (Scheme 2) [54]. The presence of an amino function at the C8-position of the quinoline skeleton is required for the specific chelation of copper.

Importantly, this series of chelators offers a well-defined square planar coordination suitable for Cu(II) but not for Cu(I). So, in the presence of glutathione (GSH), a reducing agent and a competitive ligand for copper, the Cu(II)-L complex readily releases its copper ion to glutathione to generate a Cu-GSH complex that will be able to transfer copper to regular metal carriers (Scheme 2) [61].

In such conditions, the bis(8-AQ) ligand is released and should be able to act as a catalyst
<figure><img src="image_8.png" /></figure>

**Scheme 2.** Transfer of copper from Cu–Aβ to Cu-proteins, assisted by a specific Cu(II) chelator. L stands for TDMQ20; GSH stands for glutathione. Reprinted with permission from Ref. [41]. Copyright 2019 American Chemical Society.

(Scheme 2). Bis(8-AQ) ligands may therefore be considered as suitable copper regulators of the copper homeostasis. Conversely, it was also shown that the copper complex of the mono(8-hydroxyquinoline) derivative PBT2 was unable to release copper in the presence of GSH.

On the basis of these in vitro studies, the pharmacological activity of PA1637 (Figure 4) was evaluated on a murine model of AD. The preclinical evaluation of drug candidates against AD has usually been carried out on transgenic mice [48,62,63]. However, AD is not a condition determined by a single gene mutation but a multi-parameter pathology in which a large number of age-related genes are involved. The fact that these transgenic mouse models do not accurately reflect human pathogenesis is probably one of the reasons for the failures during preclinical selection of drug candidates [64,65]. To enlarge the panel of predictable mice models, we developed a non-transgenic mouse model of AD. In regular mice (much cheaper than transgenic ones), a memory impairment similar to the early stage of AD is triggered by a single injection of Aβ₁⁻₄₂ oligomers in the mouse cerebral lateral ventricles (intracerebroventricular [icv] model) [66]. The animal model is validated by the fact that injection of the control antisense peptide Aβ₄₂⁻₁ has no effect on mouse memory and behavior. The ability of PA1637 to inhibit the episodic memory loss was evaluated on this non-transgenic murine model. After a short oral treatment with PA1637 (8 doses of PA1637, 25 mg/kg each, over a 3-week period), the episodic memory of AD mice was completely restored, similar to that of healthy animals, while that of untreated AD mice was significantly impaired [66]. These results clearly

validated the oral administration of PA1637 to fully inhibit the cognitive impairment induced by icv injection of amyloid oligomers, a way to mimic the early stage of AD. At the moment, there is no treatment able to regenerate functional neurons in the late stages of AD. An efficient drug able to stop the development of AD in the early stages will be welcome.

### 4.4. *Tetradentate mono-8-aminoquinolines* (TDMQ) against Alzheimer's disease

In spite of the capacity of PA1637 to extract copper from copper–amyloid in vitro and to inhibit the catalytic production of H₂O₂ by Cu(II)–amyloid, its development was stopped due to its rather low bioavailability. To enhance the efficiency and druggability of such copper chelators, a new series of tetradentate amine ligands (named TDMQs) was designed. TDMQs were based on a mono(8-amino)quinoline motif substituted at the C2 position by a nitrogen-containing side chain, able to offer a N4-tetradentate square planar coordination site for Cu(II) complexes, similar to that of bis(8-AQ) (Figure 4) [67,68]. Structural modulation of the polyamine chain allowed tuning the geometry of the coordination site and, consequently, the copper selectivity and the ability to inhibit oxidative stress.

In this TDMQ series, the ligands having a side chain with $n = m = 2$ (2 + 2 methylene groups), exhibited the highest affinity values for Cu(II), with log Kapp [Cu–L] values in the range 15–17, and also the highest selectivity for Cu(II) with respect to Zn(II) (ratio > 11 log units) [68]. These chelators were also able to transfer copper from Cu–Aβ to glutathione, and to inhibit the aerobic production of ROS induced by Cu–Aβ in the presence of a reductant [56]. These features are clearly related to the capacity of these N4-tetradentate ligands to offer a tetradentate square planar coordination sphere around the copper(II) ion, generating copper complexes with four nitrogen ligands in a N4 equatorial plane coordination sphere [69]. Noteworthily, bis(8-AQ) derivatives (structures depicted in Figure 4) offered the same coordination, resulting in similar correlations between the structures of the Cu(II)–L complexes and their physicochemical properties such as high affinity for Cu(II) and ability to inhibit ROS production [60].

Based on these results, TDMQ20 (Figure 4) was selected for evaluation of its anti-AD activity on three
different mouse models. An oral treatment with TDMQ20 was used to check the possibility of reversing the cognitive and behavior impairments in two non-transgenic models mimicking the early stage of AD and in a transgenic one modeling a more advanced stage of AD. In the non-transgenic mice, memory deficits were triggered by a single injection of the copper complex of amyloid Aβ<sub>1-42</sub> in the lateral ventricles (icv-CuAβ model) or hippocampus (hippo-CuAβ model) of regular mice. The third model was the classical transgenic mouse 5XFAD model [70,71].

A short oral treatment with TDMQ20 of icv-CuAβ or hippo-CuAβ mice (10 mg/kg, 8 doses over 16 days) fully restored the cognitive status evaluated by the short-term novel object recognition (NOR) assay [72], in comparison to untreated AD mice (Figure 5) [73].

By comparison, the 8-hydroxyquinoline derivative clioquinol (CQ) did not significantly improved the short-term memory of icv-CuAβ- and hippo-CuAβ mice. The level of malondialdehyde, the signature of an oxidative stress, in the cortex of icv-CuAβ was also reduced by TDMQ20. The three-month oral treatment of transgenic 5XFAD mice with TDMQ20 also resulted in behavioral improvements. Pharmacokinetic studies in rats indicated that TDMQ20 has a good bioavailability and efficiently crosses the blood-brain barrier after oral administration [74]. Noteworthy, TDMQ20 did not exhibit significant acute or chronic toxicity [73].

In addition, a three-month oral treatment of 5XFAD mice with TDMQ20 remarkably reduced the plaque loading in the cortex by about 70%, suggesting a beneficial role of TDMQ20 in clearing pathological Aβ deposits in AD mice. The treatment also significantly increased the expression of the ChAT enzyme and the CHRM4 receptor, two proteins involved in the cholinergic system [75]. All these results strongly suggest that TDMQ20 is acting on several pathways of this multifactorial disease.

Due to their reliability and easy use, the icv-CuAβ and hippo-CuAβ mice should be considered as robust non-transgenic models to evaluate the activity of potential drugs in the early stages of memory deficits. Moreover, among other possible assays [76,77], the short-term NOR test was found particularly robust to evaluate the impairment of declarative memory in mice, making it easy to select molecules for the treatment of the early stages of AD.

One should keep in mind that the few current AD therapies are not curative and provide at best a short-term improvement in symptoms, with potentially serious side effects. Moreover, their efficiency/cost ratios are questionable. Despite intensive efforts on AD over the last two decades in genetics, biochemistry, and cell biology, the pipeline of new drugs is rather unproductive. As a reference point, lecanemab, approved in the United States for the treatment of AD, is an anti-amyloid monoclonal antibody administered intravenously every other week with a post-infusion observation period with monitoring of the effect by magnetic resonance imaging. In addition to these rather strong constraints, treatment with lecanemab results in frequent and potentially severe anticoagulation side effects, and this treatment is not recommended for patients with a wide range of comorbidities, a very frequent condition in aging patients [78]. In addition, the European health agency (EMA) initially refused this treatment (July 2024) [79]. Do-nanemab, another antibody targeting amyloids recently approved by the FDA (June 2024), also induces fatal brain bleeding in a few patients [80]. These facts strongly suggest that efforts should be made to support the discovery of new "small molecules", namely chemical agents, designed for an easy crossing of the blood-brain barrier in order to produce an efficient pharmacological effect on the early stages of AD, without strong constraints or potentially severe adverse effects.

So the efficacy of TDMQ20 by oral administration at low doses on three different AD mouse models with a very low toxicity, is an encouragement for a future development of this specific copper chelator, maybe in parallel with research of other molecules targeting different mechanisms. However, considering that the introduction of a new drug candidate in the pipeline of AD treatments is rather challenging, we decided to investigate the correlation between the copper chelating activity of TDMQ20 and its therapeutic interest in a well-known copper-related disease, namely the Wilson's disease.

**5. Tetradentate mono-8-aminoquinoline TDMQ20 and Wilson's disease**

Wilson's disease (WD) is a genetic disease caused by mutations on the *Atp7b* gene coding for the copper carrier ATP7B, an ATPase in charge of incorporating
<figure><img src="image_9.png" /><figcaption>**Figure 5.** Declarative memory evaluated by the short-term novel object recognition task (NOR). The recognition index for short term memory in the icv-CuAβ and the hippo-CuAβ non-transgenic mouse models are reported in panels A and B, respectively. In each case, the recognition index of AD mice which received no drug-treatment (untreated group) was compared to that of healthy mice (control group), and to the recognition index of AD mice treated with TDMQ20 or clioquinol (CQ) (8 × 10 mg/kg in 16 days). Each mark represents the result obtained with a single mouse; horizontal lines represent mean values ± SEM. ***p < 0.001, **p < 0.01, *p < 0.05 vs. the untreated AD group (ANOVA). Adapted with permission from Figure 2 of Ref. [73]. Copyright 2020 American Chemical Society.</figcaption></figure>

copper in apoceruloplasmin in the liver, leading to the elimination of this metal ion in bile and then in feces. Deficiency in this copper carrier causes accumulation of copper in the liver, generating acute or chronic hepatitis and liver cirrhosis, potentially leading to a fulminant hepatic failure. Copper is partially released in the bloodstream and slowly eliminated in urine. In advanced stages of the disease, neurological symptoms such as seizures or Parkinsonism appear, along with psychiatric disorders. Accumulation of copper in various organs, resulting especially in renal and cardiac pathologies as well as hypoparathyroidism and osteoarticular damages, are correlated with a fatal prognosis [17,18]. Lifelong treatment is therefore necessary, using copper chelators to facilitate the excretion of copper. The first-line drugs for WD treatment via oral administration are currently D-penicillamine (DPA) and, to a lesser extent, trientine, a non-selective polyamine chelator (Figure 6) [81].

These two drugs are given at very high doses (1–2 g per day for an adult) and exhibit adverse effects that may be serious enough to require discontinuation of the treatment (in approximately 30% of patients for DPA) [82,83]. The efficacy of DPA in neurologic

<figure><img src="image_10.png" /><figcaption>**Figure 6.** Structures of copper chelators currently used in the treatment of Wilson's disease (DPA and trientine), or in development (TTM).

a Daily oral dosage for an adult [82].</figcaption></figure>

WD is only moderate (55% of improvement rate), and both DPA and trientine induce a severe and irreversible neurological worsening in 10–50% of patients with previous neurological symptoms [84]. So there is a real medical need for a specific copper chelator able to efficiently regulate the copper excess, at lower doses than those used for DPA or trientine and with lower side effects in the long term. Ammonium tetrathiomolybdate has been proposed for more than 30 years [85], recently replaced by bis-choline tetrathiomolybdate (TTM, Figure 6) [86]. The $MoS_4^{2-}$ ion chelates copper to form very stable and highly insoluble sulfur-bridged Mo–Cu
clusters [87,88] detected in the liver of WD rat models [87], resulting in accumulation of molybdenum in major organs (spleen, liver, adrenal glands, kidney, and brain) following administration of TTM [89,90]. The high affinity of TTM for copper is also responsible for inhibition of major copper enzymes such as ceruloplasmin, ascorbate oxidase, cytochrome oxidase, Cu/Zn-superoxide dismutase and tyrosinase [91].

The main drawback of DPA and trientine as ligands is their lack of selectivity in metal chelation. In fact, both drugs coordinate with high affinities a wide variety of metal ions and oxidation states [92] (see footnote¹). For example, DPA coordinates Cu²⁺ with log K₁ = 16.5, but also Cu⁺ (log K₁ = 19.5), Zn²⁺ (log K₁ = 9.6 and log β₂ = 19.6) [92], as well as Fe²⁺, Fe³⁺, Co²⁺, and Co³⁺ [93]. In addition, the structures of DPA-metal complexes can be diverse, including ternary complexes involving another amino acid such as histidine or methionine [94,95], or mixed valence Cu(I)/Cu(II) cluster complexes [96]. Moreover, the ability of DPA to act as a reductant due to its thiol functionality, in addition to its capacity to coordinate both Cu(II) and Cu(I) [or Fe(III) and Fe(II)], may confer to DPA complexes the ability to trigger deleterious Fenton-like reaction damages.

Due to the specificity of TDMQ20 for chelation of Cu(II) and the oral bioavailability of this ligand, we decided to evaluate its activity for the treatment of WD. In TX mice, a genetic model of WD [97], the overload of copper in the liver was reduced in a dose-dependent manner by a short oral treatment with TDMQ20 at doses ranging from 12.5 to 50 mg/kg/day (Figure 7a). This decrease in hepatic copper was correlated to an increase in fecal copper excretion (Figure 7b) [98]. These studies indicate that such low doses of TDMQ20 are more efficient at improving the physiological excretion pathway of copper in TX mice than DPA at 200 mg/kg/day. TDMQ20 also increases the serum concentration of ceruloplasmin (Figure 7c). Such an effect is particularly important since this concentration is a biomarker clinically

used to evaluate the efficacy of chelation therapy in patients with WD.

In addition, TDMQ20 up to 300 µM does not disturb the activity of Cu/Zn-SOD, in contrast with DPA, which inhibits Cu/Zn-SOD at a 50 µM concentration. In addition, the DPA-copper complex produces damaging ROS in vitro in the presence of a reducing agent, which is not the case with TDMQ20. In fact, DPA inhibits catalase in vitro and could be responsible for chronic inflammation through chronic disruption of H₂O₂ redox homeostasis in vivo [99]. In conclusion, TDMQ20 should be considered as a first-in-class drug candidate able to challenge DPA in the treatment of WD.

## 6. TDMQ20 copper chelator as anticancer agent

The possibility of using metal ligands in anticancer chemotherapy to regulate metal homeostasis has not been extensively explored, although it is known that the metal ion content is significantly higher in cancer cells compared to normal ones [100]. In particular, copper ions are involved in angiogenesis [101,102], which is essential for tumor growth and dissemination of cancer metastases [103,104]. It has been evidenced that copper depletion inhibits angiogenesis in cancer cells [105]. A few clinical trials have been reported with copper chelators such as DPA, trientine, or TTM, three ligands that have been documented for WD (see above, Figure 6). However, these attempts have not been successful, probably due to their lack of metal selectivity and/or potential toxicity [106]. So having TDMQ20 at hand as specific copper chelator, preliminary evaluation of its activity against different cancer cell lines was carried out. TDMQ20 was found cytotoxic against non-small cell lung carcinoma (A549), cervix cancer HeLa and hepatocarcinoma HepG2 cells, with IC₅₀ values ranging from 14 to 16 µM in vitro, lower than the reference drug 5-Fluorouracil (5-FU), and the selectivity index of TDMQ20 was higher than that of 5-FU when using non-cancer human cells as comparators. TDMQ20 also exhibited a significant anti-migration activity on HeLa cells in vitro. Mechanistic studies indicated that the activity of TDMQ20 probably involves the overproduction of ROS, with the collapse of the inner transmembrane potential in mitochondria and the induction of apoptosis [107].

$$ \overset{1}{\mathrm{K}} = \frac{[\mathrm{ML}]}{[\mathrm{M}][\mathrm{L}]} \qquad \overset{\mathrm{M}+\mathrm{L}}{\underset{\mathrm{K}_1}{\mathrm{L}}} = \overset{\mathrm{ML}}{\underset{\mathrm{K}_2}{\mathrm{L}}} = \overset{\mathrm{ML}_2}{\mathrm{L}} $$

$$ \overset{\beta_{1,2}}{\mathrm{K}_2} = \frac{[\mathrm{ML}_2]}{[\mathrm{ML}][\mathrm{L}]} \qquad \overset{\beta_{1,2}}{\mathrm{K}_1} = \frac{[\mathrm{ML}_2]}{[\mathrm{M}][\mathrm{L}]^2} = \overset{\beta_{1,2}}{\mathrm{K}_1 \mathrm{K}_2} $$
(usually noted $\beta_2$)
<figure><img src="image_11.png" /><figcaption>**Figure 7.** Concentration of copper in liver (a) and feces (b) in mg/kg, and of ceruloplasmin in serum (c) of TX mice (WD) after oral treatment with TDMQ20 at 12.5 mg/kg/d (TDMQ20-L), 25 mg/kg/d (TDMQ20-M), or 50 mg/kg/d (TDMQ20-H). WD mice orally treated by DPA at 200 mg/kg/d are given for comparison. Control mice are healthy C57BL/6 mice bearing no mutation on ATP7B. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001 and \*\*\*\*p < 0.0001. Adapted from Ref. [98].</figcaption></figure>

## 7. Conclusion

Since copper plays essential functions in human body, this metal ion can be considered as a promising therapeutic target in several diseases. A twenty-five-year review of the state of the art in rational chelator design has led us from phenanthroline derivatives to the N4-tetradentate mono-8-aminoquinoline series, especially the TDMQ20 as a suitable copper(II) chelator for therapeutic use. Due to its optimized coordination properties, this specific Cu(II) ligand exhibits a promising activity on murine models of Alzheimer's and Wilson's diseases, two diseases involving copper dyshomeostasis and copper accumulation, respectively. Clinical development of TDMQ20 as a therapeutic alternative to DPA for normalizing copper levels in WD patients is currently under discussion. In addition, this chelator is more active than the reference drug 5-FU on several human cancer cell lines. Future clinical developments will be necessary to evidence which therapeutic domain will be best tackled by TDMQ20.

As a concluding remark, the specificity for copper chelation and the structure and properties of the corresponding copper complex are prerequisites parameters in the design of pharmacological ligands suitable for targeting diseases triggered by the pathological disruption of copper homeostasis.

## Data availability

All data presented in this review article have been reported in the cited articles of our group and in the associated supporting information.

## Acknowledgments

Authors gratefully acknowledge all colleagues, post-doctoral fellows, PhD and master students, and collaborators who have been involved in the research of specific metal regulators as potential drugs.

## Declaration of interests

The authors do not work for, advise, own shares in, or receive funds from any organization that could benefit from this article, and have declared no affiliations other than their research organizations.

## Funding

Financial support was received from the CNRS, Inserm, and GDUT.

## References

[1] J. J. R. Frausto da Silva and R. J. P. Williams, *The Biological Chemistry of the Elements: The Inorganic Chemistry of Life*, Oxford University Press: Oxford, 2001.
[2] E. D. Gaier, B. A. Eipper and R. E. Mains, "Copper signaling in the mammalian nervous system: synaptic effects", *J. Neurosci. Res.* **91** (2012), pp. 2–19.

[3] J. J. P. Perry, D. S. Shin, E. D. Getzoff and J. A. Tainer, "The structural biochemistry of the superoxide dismutases", *Biochem. BioPhys. Acta* **180** (2010), pp. 245–262.

[4] E. I. Solomon, U. M. Sundaram and T. E. Machonkin, "Multicopper oxidases and oxygenases", *Chem. Rev.* **96** (1996), pp. 2563–2605.

[5] G. Babcock, L. E. Vickery and G. Palmer, "The electronic state of heme in cytochrome oxidase II", *J. Biol. Chem.* **253** (1978), pp. 2400–2411.

[6] D. A. Rowley and B. Halliwell, "Formation of hydroxyl radicals from NADH and NADPH in the presence of copper salts", *J. Inorg. Biochem.* **23** (1985), pp. 103–108.

[7] B. E. Kim, T. Nevitt and D. J. Thiele, "Mechanisms for copper acquisition, distribution and regulation", *Nature Chem. Biol.* **4** (2008), pp. 176–185.

[8] W. Lai, Q. Wei, J. Zhuang, M. Lu and D. Tang, "Fenton reaction-based colorimetric immunoassay for sensitive detection of brevetoxin, B", *Biosens. Bioelectron.* **80** (2016), pp. 249–256.

[9] M. A. Lovell, J. D. Robertson, W. J. Teesdale, J. L. Campbell and W. R. Markesbery, "Copper, iron and zinc in Alzheimer's disease senile plaques", *J. Neurol. Sci.* **158** (1998), pp. 47–52.

[10] C. S. Atwood, R. C. Scarpa, X. Huang, R. D. Moir, W. D. Jones, D. P. Fairlie, R. E. Tanzi and A. I. Bush, "Characterization of copper interactions with Alzheimer amyloid β-peptides: identification of an attomolar-affinity copper bonding site on amyloid β₁–₄₂", *J. Neurochem.* **75** (2000), pp. 1219–1233.

[11] A. Robert, Y. Liu, M. Nguyen and B. Meunier, "Regulation of copper and iron homeostasis by metal chelators: a possible chemotherapy for Alzheimer's disease", *Acc. Chem. Res.* **48** (2015), pp. 1332–1339.

[12] J. S. Valentine, P. A. Doucette and S. Z. Potter, "Copper-zinc superoxide dismutase and amyotrophic lateral sclerosis", *Ann. Rev. Biochem.* **74** (2005), pp. 563–593.

[13] D. J. Waggoner, T. B. Bartnikas and J. D. Gitlin, "The role of copper in neurodegenerative disease", *Neurobiol. Dis.* **6** (1999), pp. 221–230.

[14] M. Rios, B. Habecker, T. Sasaoka, G. Eisenhofer, H. Tian, S. Landis, D. Chikaraishi and S. Roffler-Tarlov, "Catecholamine synthesis is mediated by tyrosinase in the absence of tyrosine hydroxylase", *J. Neurosci.* **19** (1999), pp. 3519–3526.

[15] T. Xiao, C. M. Ackerman, E. C. Carroll, et al., "Copper regulates rest-activity cycles through the locus coeruleus-norepinephrine system", *Nat. Chem. Biol.* **14** (2018), pp. 655–663.

[16] O. Bandmann, K. H. Weiss and S. G. Kaler, "Wilson's disease and other neurological copper disorders", *Lancet Neurol.* **14** (2015), pp. 103–113.

[17] A. Lucena-Valera, D. Perez-Palacios, R. Muñoz-Hernandez, M. Romero-Gómez and J. Ampuero, "Wilson's disease: revisiting an old friend", *World J. Hepatol.* **13** (2021), pp. 634–649.

[18] J. R. Forbes, G. Hsi and D. W. Cox, "Role of the copper-binding domain in the copper transport function of ATP7B, the P-type ATPase defective in Wilson disease", *J. Biol. Chem.* **274** (1999), pp. 12408–12413.

[19] B. X. Wong, A. Tsatsanis, L. Q. Lim, P. A. Adlard, A. I. Bush and J. A. Duce, "β-Amyloid precursor protein does not possess ferroxidase activity but does stabilize the cell surface ferrous iron exporter ferroportin", *PLoS One* **9** (2014), article no. e114174.

[20] D. S. Sigman, A. Mazumder and D. M. Perrin, "Chemical nucleases", *Chem. Rev.* **93** (1993), pp. 2295–2316.

[21] G. Pratviel, J. Bernadou and B. Meunier, "DNA and RNA cleavage by metal complexes", *Adv. Inorg. Chem.* **45** (1998), pp. 251–312.

[22] G. Pratviel, J. Bernadou and B. Meunier, "Carbon-hydrogen bonds of DNA sugar units as targets for chemical nucleases and drugs", *Angew. Chem. Int. Ed.* **34** (1995), pp. 746–769.

[23] J. M. Veal, K. Merchant and R. L. Rill, "The influence of reducing agent and 1,10-phenanthroline concentration on DNA cleavage by phenanthroline + copper", *Nucleic Acids Res.* **19** (1991), pp. 3383–3388.

[24] C. Queffélec, P. Baran Pati and Y. Pellegrin, "Fifty shades of phenanthroline: synthesis strategies to functionalize 1,10-Phenanthroline in all positions", *Chem. Rev.* **124** (2024), pp. 6700–6902.

[25] B. James and R. J. P. Williams, "The oxidation-reduction potentials of some copper complexes", *J. Chem. Soc.* (1961), pp. 2007–2019.

[26] M. Pitié, B. Donnadieu and B. Meunier, "Preparation of the new bis(phenanthroline) ligand "Clip-Phen" and evaluation of the nuclease activity of the corresponding copper complex", *Inorg. Chem.* **37** (1998), pp. 3486–3489.

[27] M. Pitié, B. Sudres and B. Meunier, "Dramatic increase of the DNA cleavage activity of Cu(Clip-phen) by fixing the bridging linker on the C3 position of the phenanthroline units", *Chem. Commun.* (1998), pp. 2597–2598.

[28] M. Pitié, C. Boldron, H. Gornitzka, C. Hemmert, B. Donnadieu and B. Meunier, "DNA Cleavage by copper complexes of 2- and 3-Clip-Phen derivatives", *Eur. J. Inorg. Chem.* (2003), pp. 528–540.

[29] M. Pitié and B. Meunier, "Preparation of a spermine conjugate of the bis-phenanthroline ligand Clip-Phen and evaluation of the corresponding copper complex", *Bio-conjugate Chem.* **9** (1998), pp. 604–611.

[30] A. Casini and A. Pothig, "Metals in cancer research: beyond platinum metallodrugs", *ACS Centr. Sci.* **10** (2024), pp. 242–250.

[31] A. De Vizcaya Ruiz, A. Rivero-Muller, L. Ruiz-Ramirez, G. E. N. Kass, L. R. Kelland, R. M. Orr and M. Dobrota, "Induction of apoptosis by a novel copper-based anticancer compound-Casiopéina II in L1210 murine leukaemia and CH1 human ovarian carcinoma", *Tox. In Vitro* **14** (2000), pp. 1–5.

[32] I. Gracia-Mora, L. Ruiz-Ramirez, C. Gomez-Ruiz, et al., "Knight's move in the periodic table, from copper to platinum, novel antitumor mixed chelate copper compounds, casiopeina, evaluated by an in vitro human and
murine cancer cell line panel", *Met. Based Drugs* **8** (2001),
pp. 19–28.

[33] M. Pitié, A. Croisy, D. Carrerz, C. Boldron and B. Meunier, "Cytostatic activity of 1,10-phenanthroline derivatives generated by the Clip-Phen strategy", *ChemBioChem* **6** (2005), pp. 686-691.

[34] C. Deegan, B. Coyle, M. McCann, M. Dev-
ereux and D. A. Egan, "In vitro anti-tumour ef-
fect of 1,10-phenanthroline-5,6-dione (phen-
dione), [Cu(phendione)₃][ClO₄)₂·4H₂O and
[Ag(phendione)₂]ClO₄ using human epithelial cell
lines", *Chem. Biol. Interact.* **164** (2006), pp. 115–125.

[35] J. C. García-Ramos, G. Vértiz-Serrano, L. Macías-Rosales, R. Galindo-Murillo, Y. Toledano-Magaña, J. P. Bernal, F. Cortés-Guzmán and L. Ruiz-Azuara, "Isomeric effect on the pharmacokinetic behavior of anticancer CuII mixed chelate complexes: experimental and theoretical approach", *Eur. J. Inorg. Chem.* (2017), pp. 1728-1736.

[36] P. H. Alves Machado, D. A. Paixão, R. Campos Lino, et al., "A selective CuII complex with 4-fluorophenoxyacetic acid hydrazide and phenanthroline displays DNA-cleaving and pro-apoptotic properties in cancer cells", *Sci. Rep.* **11** (2021), article no. 24450.

[37] M. A. Uvarova, I. A. Lutsenko, M. A. Shmelev, S. E. Nefedov, O. B. Bekker, A. I. Lashkin, V. O. Shender and I. L. Eremenko, "Research of the influence of anions in complexes [CuPhen(Hpz)₂X₂] (X = CF₃COO⁻, Otf⁻, Cl⁻) on the structure and bioactivity", *New J. Chem.* **48** (2024), pp. 717-723.

[38] K. J. Barnham and A. I. Bush, "Biological metals and metal-targeting compounds in major neurodegenerative diseases", *Chem. Soc. Rev.* **43** (2014), pp. 6727-6749.

[39] K. P. Kepp, "Alzheimer's disease: How metal ions define β-amyloid function", *Coord. Chem. Rev.* **351** (2017), pp. 127-159.

[40] L. Guilloreau, S. Combalbert, A. Sournia-Saquet, H. Mazarguil and P. Faller, "Redox chemistry of copper-amyloid-beta: the generation of hydroxyl radical in the presence of ascorbate is linked to redox-potentials and aggregation state", *ChemBioChem* **8** (2007), pp. 1317–1325.

[41] Y. Liu, M. Nguyen, A. Robert and B. Meunier, "Metal ions in Alzheimer's disease: a key role or not?", *Acc. Chem. Res.* **52** (2019), pp. 2026–2035.

[42] S. J. C. Lee, E. Nam, H. J. Lee, M. G. Savelieff and M. H. Lim, "Towards an understanding of amyloid-beta oligomers: characterization, toxicity mechanisms, and inhibitors", *Chem. Soc. Rev.* **46** (2017), pp. 310–323.

[43] E. G. McGeer and P. L. McGeer, "Brain inflammation in Alzheimer disease and the therapeutic implications", *Curr. Pharm. Des.* **5** (1999), pp. 821–836.

[44] T. A. Bayer, S. Schäfer, A. Simons, et al., "Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice", *Proc. Natl. Acad. Sci. USA* **100** (2003), pp. 14187-14192.

[45] P. Faller and C. Hureau, "A Bioinorganic View of Alzheimer's Disease: when misplaced metal ions (re)direct the electrons to the wrong target", *Chem. Eur. J.* **18** (2012), pp. 15910–15920.

[46] L. R. Perez and K. J. Franz, "Minding metals: tailoring multifunctional chelating agents for neurodegenerative disease", *Dalton Trans.* **39** (2010), pp. 2177-2187.

[47] R. A. Cherny, C. S. Atwood, M. E. Xilinas, et al., "Treat-
ment with a copper-zinc chelator markedly and rapidly
inhibits beta-amyloid accumulation in Alzheimer's dis-
ease transgenic mice", *Neuron* **30** (2001), pp. 665–676.

[48] N. G. Faux, C. W. Ritchie, A. Gunn, et al., "PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses", *J. Alzheimer's Dis.* **20** (2010), pp. 509–516.

[49] D. A. Andersson, C. Gentry, S. Moss and S. Bevan, "Clio-
quinol and pyrithione activate TRPA1 by increasing in-
tracellular Zn²⁺", *Proc. Natl. Acad. Sci. USA* **109** (2009),
pp. 8374-8379.

[50] A. Takeda, S. Takada, M. Ando, K. Itagaki, H. Tamano, M. Suzuki, H. Iwaki and N. Oku, "Impairment of recognition memory and hippocampal long-term potentiation after acute exposure to cloquinol", *Neuroscience* **171** (2010), pp. 443-450.

[51] J. P. Phillips, "The reactions of 8-quinolinol", *Chem. Rev.* **56** (1956), pp. 271-297.

[52] E. Ferrada, V. Arancibia, B. Loeb, E. Norambuena, C. Olea-
Azar and J. P. Huidobro-Toro, "Stoichiometry and con-
ditional stability constants of Cu(II) or Zn(II) cloquinol
complexes; implications for Alzheimer's and Hunt-
ington's disease therapy", *Neurotoxicology* **28** (2007),
pp. 445-449.

[53] A. Therapeutics, *Prana Biotechnology Announces Top-Line Results of Phase 2 IMAGINE Trial of PBT2 in Alzheimer's Disease*, 2014. Online at https://alteritytherapeutics.com/investor-centre/news/2014/03/31/prana-biotechnology-announces-top-line-results-phase-2-imagine-trial-pbt2-alzheimers-disease/ (accessed on September 18, 2025).

[54] M. Nguyen, A. Robert, A. Sournia-Saquet, L. Vendier and B. Meunier, "The necessity of having a tetradentate ligand to extract copper(ii) ions from amyloids", *ChemistryOpen* **4** (2015), pp. 27-31.

[55] M. Nguyen, L. Vendier, J.-L. Stigliani, B. Meunier and A. Robert, "Structures of the copper and zinc complexes of PBT2, a chelating agent evaluated as potential drug for neurodegenerative diseases", *Eur. J. Inorg. Chem.* (2017), pp. 600–608.

[56] W. Zhang, Y. Liu, C. Hureau, A. Robert and B. Meunier, "N4-Tetradentate chelators efficiently regulate copper homeostasis and prevent ROS production induced by copper-amyloid-β₁⁻₁₆, even in the presence of an excess of zinc", *Chem. Eur. J.* **24** (2018), pp. 7825-7829.

[57] C. Deraeve, M. Pitié, H. Mazarguil and B. Meunier, "Bis-
8-hydroxyquinoline ligands as potential anti-Alzheimer
agents", *New J. Chem.* **31** (2007), pp. 193–195.

[58] C. Deraeve, C. Boldron, A. Maraval, H. Mazarguil, H. Gor-
nitzka, L. Vendier, M. Pitié and B. Meunier, "Prepara-
tion and study of new poly-8-hydroxyquinoline chelators
for an anti-Alzheimer strategy", *Chem. Eur. J.* **14** (2008),
pp. 682–696.

[59] S. Noël, S. Bustos Rodriguez, S. Sayen, E. Guillon, P. Faller and C. Hureau, "Use of a new water-soluble Zn sensor
to determine Zn affinity for the amyloid-β peptide and relevant mutants", *Metallomics* **6** (2014), pp. 1220-1222.

[60] M. Nguyen, A. Robert, A. Sournia-Saquet, L. Vendier and B. Meunier, "Characterization of new specific copper chelators as potential drugs for the treatment of Alzheimer's disease", *Chem. Eur. J.* **20** (2014), pp. 6771-6785.

[61] M. Nguyen, C. Bijani, N. Martins, B. Meunier and A. Robert, "Transfer of copper from an amyloid to a natural copper-carrier peptide with a specific mediating ligand", *Chem. Eur. J.* **21** (2015), pp. 17085-17090.

[62] J. F. Quinn, C. J. Harris, K. E. Cobb, C. Domes, M. Ralle, G. Brewer and T. L. Wadsworth, "A copper-lowering strategy attenuates amyloid pathology in a transgenic mouse model of Alzheimer's disease", *J. Alzheimer's Dis.* **21** (2010), pp. 903-914.

[63] P. A. Adlard, L. Bica, A. R. White, et al., "Metal ionophore treatment restores dendritic spine density and synaptic protein levels in a mouse model of Alzheimer's disease", *PLoS One* **6** (2011), article no. e17669.

[64] K. R. Zahs and K. H. Ashe, ""Too much good news" – are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease?", *Trends Neurosci.* **33** (2010), pp. 381-389.

[65] "Editorial. "Why are drug trials in Alzheimer's disease failing?", *The Lancet* **376** (2010), pp. 658-658.

[66] J. Ceccom, F. Coslédan, H. Halley, B. Francès, J.-M. Lasalle and B. Meunier, "Copper chelator induced efficient episodic memory recovery in a non-transgenic Alzheimer's mouse model", *PLoS One* **7** (2012), article no. e43105.

[67] Y. Liu, X. Liu, D. Huang, M. Huang, D. Wang, M. Nguyen, A. Robert and B. Meunier, Four-tooth chelating single quinoline derivative, preparation method thereof and application as metal ion regulator for neurodegenerative disease, CN patent, 201610369550.X, 2016.

[68] W. Zhang, D. Huang, M. Huang, et al., "Preparation of tetradentate copper chelators as potential anti-Alzheimer agents", *ChemMedChem* **13** (2018), pp. 684-704.

[69] Y. Li, M. Nguyen, M. Baudoin, L. Vendier, Y. Liu, A. Robert and B. Meunier, "Why is tetradentate coordination essential for potential copper homeostasis regulators in Alzheimer's disease?", *Eur. J. Inorg. Chem.* (2019), pp. 4712-4718.

[70] H. Oakley, S. L. Cole, S. Logan, et al., "Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation", *J. Neurosci.* **26** (2006), pp. 10129-10140.

[71] S. Jawhar, A. Trawicka, C. Jenneckens, T. A. Bayer and O. Wirths, "Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intra-neuronal Aβ aggregation in the 5XFAD mouse model of Alzheimer's disease", *Neurobiol. Aging* **33** (2012), 196.e29-196.e40.

[72] B. Grayson, M. Leger, C. Piercy, L. Adamson, M. Harte and J. C. Neill, "Assessment of disease-related cognitive impairments using the novel object recognition (NOR) task in rodents", *Behav. Brain Res.* **285** (2015), pp. 176-193.

[73] J. Zhao, Q. Shi, H. Tian, et al., "TDMQ20, a specific copper chelator, reduces memory impairments in Alzheimer's disease mouse models", *ACS Chem. Neurosci.* **12** (2021), pp. 140-149.

[74] L. Huang, Y. Zeng, Y. Li, Y. Zhu, Y. He, Y. Liu, A. Robert and B. Meunier, "Distribution in rat blood and brain of TDMQ20, a copper chelator designed as a drug-candidate for Alzheimer's disease", *Pharmaceutics* **14** (2022), article no. 2691.

[75] F. Sun, J. Zhao, H. Zhang, Q. Shi, Y. Liu, A. Robert, Q. Liu and B. Meunier, "System and synaptic transmission in a mouse model of Alzheimer's disease", *ACS Chem. Neurosci.* **13** (2022), pp. 3093-3107.

[76] A. K. Kraeuter, P. C. Guest and Z. Sarnyai, "The Y-maze for assessment of spatial working and reference memory in mice", *Methods Mol. Biol.* **1916** (2019), pp. 105-111.

[77] A. A. Walf and C. A. Frye, "The use of the elevated plus maze as an assay of anxiety-related behavior in rodents", *Nat. Protoc.* **2** (2007), pp. 322-328.

[78] J. Cummings, L. Apostolova, G. Rabinovici, et al., "Alzheimer's disease and related disorders therapeutics work group, Lecanemab: appropriate use recommendations", *J. Prev. Alzheimers Dis.* **10** (2023), pp. 362-377.

[79] E. M. Agency, *Questions and Answers on the Approval and Marketing Authorisation of Leqembi (Lecanemab)*, 2024. Online at https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-approval-marketing-authorisation-leqembi-lecanemab_en.pdf (accessed on October 7, 2025).

[80] J. Couzin-Frankel, "New Alzheimer's drug clears FDA advisory vote despite unknowns", *Science* **384** (2024), pp. 1164-1165.

[81] J. M. Walshe, "The conquest of Wilson's disease", *Brain* **132** (2009), pp. 2289-2295.

[82] K. H. Weiss, F. Thurik, D. N. Gotthardt, et al., "EUROW-ILSON Consortium. Efficacy and safety of oral chelators in treatment of patients with Wilson disease", *Clin. Gas-troenterol. Hepatol.* **11** (2013), pp. 1028-1035.

[83] E. A. Roberts and M. L. Schilsky, "American Association for Study of Liver Diseases (AASLD), diagnosis and treatment of Wilson disease: an update", *Hepatology* **47** (2008), pp. 2089-2111.

[84] G. J. Brewer, "Neurologically presenting Wilson's disease: epidemiology, pathophysiology and treatment", *CNS Drugs* **19** (2005), pp. 185-192.

[85] G. J. Brewer, R. D. Dick, V. Johnson, Y. Wang, V. Yuzbasiyan-Gurkan, K. Kluin, J. K. Fink and A. Aisen, "Treatment of Wilson's disease with ammonium tetrathiomolybdate", *Arch. Neurol.* **51** (1994), pp. 545-554.

[86] K. H. Weiss, F. K. Askari, A. Czlonkowska, et al., "Bis-choline tetrathiomolybdate in patients with Wilson's disease: an open-label, multi-centre, phase 2 study", *Lancet Gastroenterol. Hepatol.* **2** (2017), pp. 869-876.

[87] G. N. George, I. J. Pickering, H. H. Harris, J. Gailer, D. Klein, J. Lichtmannegger and K.-H. Summer, "Tetrathiomolybdate causes formation of hepatic task in rodents", *Behav. Brain Res.* **285** (2015), pp. 176-193.
copper-molybdenum clusters in an animal model of
Wilson's disease", *J. Am. Chem. Soc.* **125** (2003), pp. 1704–1705.

[88] G. R. Helz and B. E. Erickson, "Extraordinary stability of copper(I)-tetrathiomolybdate complexes: possible implication for aquatic ecosystems", *Environ. Toxicol. Chem.* **30** (2011), pp. 97–102.

[89] Y. Plitz and L. Boyling, "Metabolic disposition of WTX101 (bis-choline tetrathiomolybdate) in a rat model of Wilson's disease", *Xenobiotica* **49** (2019), pp. 332–338.

[90] J. R. Foster, K. Billimoria, M. E. del Castillo Busto, S. Strekopytov, H. Goenaga-Infante and T. J. Morley, "Accumulation of molybdenum in major organs following repeated oral administration of bis-choline tetrathiomolybdate in the Sprague Dawley rat", *J. Appl. Toxicol.* **42** (2022), pp. 1807–1821.

[91] H. M. Alvarez, Y. Xue, C. D. Robinson, et al., "Tetrathiomolybdate inhibits copper trafficking proteins through metal cluster formation", *Science* **327** (2010), pp. 331–334.

[92] A. E. Martell (ed.), in *Stability Constants of Metal-ion Complexes*, 2nd edition, Royal Society of Chemistry: London, 1971.

[93] L. G. Stadtherr and R. B. Martin, "Iron(II) and iron(III) complexes of penicillamine", *Inorg. Chem.* **11** (1972), pp. 92–94.

[94] P. de Meester and D. J. Hodgson, "Model for the binding of D-penicillamine to metal ions in living systems: synthesis and structure of L-histidinyl-D-penicillaminatocobalt(III) monohydrate, [Co(L-His)(D-Pen)]•H₂O", *J. Am. Chem. Soc.* **99** (1977), pp. 101–104.

[95] B. B. Tewari, "Studies on complexation in solution with a paper electrophoretic technique [The system copper(II)/cobalt(II)-methionine-penicillamine]", *J. Chem. Eng. Data* **55** (2010), pp. 1779–1783.

[96] P. J. M. W. L. Birker and H. C. Freeman, "Structure, properties, and function of a copper(I)-copper(II) complex of D-penicillamine: Pentathallium(I) 8-chloro-dodeca(D-

penicillaminato)-octocuprate(I)hexacuprate(II) n-
hydrate", *J. Am. Chem. Soc.* **99** (1977), pp. 6890–6899.

[97] M. B. Theophilos, D. W. Cox and J. F. B. Mercer, "The toxic milk model is a murine model of Wilson disease", *Human Mol. Genet.* **5** (1996), pp. 1619–1624.

[98] Y. Zhu, Y. Tang, L. Huang, M. Nguyen, Y. Liu, A. Robert and B. Meunier, "The specific copper(II) chelator TDMQ20 is efficient for the treatment of Wilson's disease in mice", *Pharmaceutics* **15** (2023), article no. 2719.

[99] D. Padovani and E. Galardon, "Molecular basis for the in-
teraction of catalase with D-penicillamine: rationaliza-
tion of some of its deleterious effects", *Chem. Res. Toxi-
col.* **35** (2022), pp. 412–421.

[100] D. Yoshida, Y. Ikeda and S. Nakazawa, "Quantitative analysis of copper, zinc and copper/zinc ratio in selected human brain tumors", *J. Neurooncol.* **16** (1993), pp. 109–115.

[101] E. Urso and M. Maffia, "Behind the link between copper and angiogenesis: established mechanisms and an overview on the role of vascular copper transport systems", *J. Vasc. Res.* **52** (2015), pp. 172–196.

[102] L. Chen, J. Min and F. Wang, "Copper homeostasis and cuproptosis in health and disease", *Signal Transduct. Target. Ther.* **7** (2022), article no. 378.

[103] S. Ishida, P. Andreux, C. Poitry-Yamate, J. Auwerx and D. Hanahan, "Bioavailable copper modulates oxidative phosphorylation and growth of tumors", *Proc. Natl. Acad. Sci. USA* **110** (2013), pp. 19507–19512.

[104] E. J. Ge, A. I. Bush, A. Casini, et al., "Connecting copper and cancer: from transition metal signalling to metalloplasia", *Nat. Rev. Cancer* **22** (2022), pp. 102–113.

[105] L. Finney, S. Vogt, T. Fukai and D. Glesne, "Copper and angiogenesis: unravelling a relationship key to cancer progression", *Clin. Exp. Pharmacol. Physiol.* **36** (2009), pp. 88–94.

[106] C. Santini, M. Pellei, V. Gandin, M. Porchia, F. Tisato and C. Marzano, "Advances in copper complexes as anticancer agents", *Chem. Rev.* **114** (2014), pp. 815–862.

[107] Y. Guan, M. Nguyen, A. Robert, Y. Liu and B. Meunier, "Copper selective 8-aminoquinoline based tetradentate chelators as anticancer agents", *RSC Med. Chem.* **15** (2024), pp. 3048–3056.